Form 4: Ultragenyx CFO Sells Shares in Pre-Arranged Trade

Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, sold 3,081 shares of common stock for $36.38 per share under a Rule 10b5-1 plan.

Summary

• Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc. (RARE), reported a sale of common stock.
• The transaction involved the disposition of 3,081 shares of common stock.
• The shares were sold at a price of $36.38 per share.
• The total value of the transaction is approximately $112,087.58 (3,081 shares * $36.38/share).
• Following this transaction, Mr. Horn beneficially owns 95,146 shares of common stock.
• The sale was executed on December 10, 2025, and was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction.

Sentiment

Score: 5

Explanation: A neutral score. While an insider sale can sometimes be viewed negatively, the execution under a Rule 10b5-1 plan suggests a pre-planned, routine diversification rather than a lack of confidence in the company's future. It's a factual report of a transaction with no explicit positive or negative company news.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than a reaction to recent company news, which can mitigate negative interpretations.

Negatives

• An insider sale, even if pre-scheduled, can sometimes be perceived negatively by the market as it reduces management's direct equity stake in the company.

Industry Context

Insider sales are common across all industries, particularly when executed under Rule 10b5-1 plans, which allow executives to diversify their holdings without being accused of trading on material non-public information. In the biotechnology sector, executives often hold significant equity, and such sales are a routine part of personal financial planning.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal, though the Rule 10b5-1 plan mitigates concerns about opportunistic selling. The direct impact on other stakeholders like employees, customers, or suppliers is minimal from this specific transaction.

Key Dates

Recommendation

The reported transaction is a routine insider sale executed under a Rule 10b5-1 plan, which typically indicates a pre-scheduled diversification of holdings rather than a change in management's outlook on the company. This filing alone does not provide sufficient new information to warrant a change in investment recommendation. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

Ultragenyx Pharmaceutical, RARE, Insider Trading, Form 4, Stock Sale, CFO, Howard Horn, Rule 10b5-1